Quanterix boosts NfL assays with UmanDiagnostics acquisition

By LabPulse.com staff writers

June 27, 2019 -- Quanterix is building its testing offerings for neurofilament light (NfL) -- an increasingly important biomarker in Alzheimer's disease and other neurological conditions -- through its $16 million acquisition of Swedish NfL antibody supplier UmanDiagnostics.

In a statement about the deal, Quanterix said the acquisition secures the supply of highly specific NfL antibodies for use in its Simoa NfL assays and services and should accelerate the availability of diagnostics.

Quanterix also noted that its first test for measuring NfL in blood was developed with UmanDiagnostics' antibodies. NfL can be measured in cerebrospinal fluid, but interest in a noninvasive blood test is growing. The marker is important for a range of neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, traumatic brain injury, and multiple sclerosis.

UmanDiagnostics will continue to sell NfL antibodies and enzyme-linked immunosorbent assay (ELISA) kits to other companies. Quanterix plans to develop new NfL applications and assays through the acquisition; it noted that serum NfL is being used in 46 active clinical trials and believes the market for diagnostics is worth about $10 billion.

Evidence builds for Alzheimer's beta-amyloid blood test
Blood-based biomarker testing for Alzheimer's disease performed well in two prospective studies for assessing beta-amyloid plaque buildup in the brain....
Cerebrospinal fluid test helps pinpoint dementia disorders
Testing for neurofilament light protein in cerebrospinal fluid appears to be helpful for differentiating some neurological conditions, such as frontotemporal...
Blood tau test works as biomarker for deadly Creutzfeldt-Jakob disease
Testing for the tau protein in blood could help predict the outlook for the rare and deadly Creutzfeldt-Jakob disease, a discovery that also has implications...

Copyright © 2019 LabPulse.com